#1 Clinical Trials Search in Europe

Lenalidomide

Lenalidomide, also known by its brand name Revlimid, is an immunomodulatory drug that has shown promise in treating various types of cancer. This article explores the use of lenalidomide in clinical trials for conditions such as multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and myelodysplastic syndromes. We’ll examine how lenalidomide is being studied alone and in combination with other treatments to potentially improve outcomes for patients with these challenging diseases.

Table of Contents

What is Lenalidomide?

Lenalidomide is a powerful medication used in the treatment of various blood cancers and disorders. It’s also known by its brand name Revlimid[1]. Lenalidomide belongs to a class of drugs called immunomodulators, which means it can modify or regulate the functioning of the immune system[2].

What Conditions Does Lenalidomide Treat?

Lenalidomide is used to treat several conditions, including:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells in the bone marrow[3]
  • Myelodysplastic Syndromes (MDS): A group of disorders where blood cells in the bone marrow don’t mature properly[4]
  • Follicular Lymphoma: A type of non-Hodgkin lymphoma that affects white blood cells called lymphocytes[1]
  • Mantle Cell Lymphoma: Another type of non-Hodgkin lymphoma[1]
  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow[2]

How Does Lenalidomide Work?

Lenalidomide works in several ways to combat cancer and blood disorders:

  • It helps the immune system fight cancer cells[1]
  • It can stop or slow the growth of cancer cells[2]
  • It may block blood flow to tumors, preventing their growth[2]
  • In some cases, it can help bone marrow produce normal blood cells in conditions like MDS[4]

How is Lenalidomide Administered?

Lenalidomide is typically taken orally (by mouth) in capsule form. The dosage and schedule can vary depending on the condition being treated and the individual patient’s needs. Some common administration patterns include:

  • Daily for 21 days out of a 28-day cycle[5]
  • Continuous daily dosing[3]
  • In combination with other medications, such as dexamethasone or chemotherapy drugs[6]

Lenalidomide in Clinical Trials

Lenalidomide is being studied in numerous clinical trials to explore its effectiveness in various conditions and in combination with other treatments. Some areas of ongoing research include:

  • Use in newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant[7]
  • Combination therapy with other novel agents like elranatamab and daratumumab[7]
  • Treatment of relapsed or refractory (hard-to-treat) blood cancers[2]
  • Use in specific genetic subtypes of myelodysplastic syndromes[4]

Potential Side Effects

Like all medications, lenalidomide can cause side effects. Some potential side effects include:

  • Fatigue
  • Diarrhea
  • Nausea
  • Constipation
  • Rash
  • Decreased blood cell counts (which can lead to anemia, increased risk of infections, or bleeding)
  • Blood clots (in rare cases)[2]

It’s important to discuss potential side effects with your healthcare provider, as they can help manage these issues and may adjust your treatment if necessary.

Important Considerations for Patients

If you’re considering or currently taking lenalidomide, keep these points in mind:

  • Lenalidomide can cause birth defects, so it’s crucial to use effective birth control and avoid pregnancy while taking this medication[2]
  • Regular blood tests will be necessary to monitor your blood cell counts and overall health
  • Inform your doctor about all other medications you’re taking, as lenalidomide can interact with other drugs
  • Follow your prescribed dosing schedule carefully, and don’t stop taking the medication without consulting your doctor
  • Report any unusual symptoms or side effects to your healthcare provider promptly

Remember, lenalidomide is a powerful medication that has shown significant benefits for many patients with blood cancers and disorders. However, it’s essential to work closely with your healthcare team to ensure it’s the right treatment for you and to manage your care effectively.

Aspect Details
Cancer Types Studied Multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, myelodysplastic syndromes
Administration Oral, typically once daily for 21 days in 28-day cycles
Dosage Range 5 mg to 25 mg daily, depending on the study and condition
Combination Therapies Rituximab, RICE (rituximab, ifosfamide, carboplatin, etoposide), dexamethasone
Study Objectives Improve overall response rates, progression-free survival, overall survival; evaluate as maintenance therapy
Common Side Effects Fatigue, diarrhea, neutropenia, thrombocytopenia, anemia
Serious Adverse Events Monitored Blood clots, secondary malignancies, tumor flare reactions
Notable Study Designs Dose escalation studies, randomized trials comparing to standard care, maintenance therapy post-transplant

FAQ

  • What types of cancer is lenalidomide being studied for in clinical trials? Lenalidomide is being studied in clinical trials for several types of cancer, including multiple myeloma, chronic lymphocytic leukemia (CLL), mantle cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and myelodysplastic syndromes (MDS) associated with deletion 5q.
  • How is lenalidomide typically administered in these trials? In most trials, lenalidomide is administered orally, usually once daily. The dosing schedule often involves taking the medication for 21 days followed by a 7-day rest period, creating a 28-day cycle. However, the exact dosage and schedule can vary depending on the specific trial and condition being treated.
  • What are some common combination therapies being studied with lenalidomide? Lenalidomide is being studied in combination with various other treatments. Some examples include rituximab for follicular lymphoma, RICE (rituximab, ifosfamide, carboplatin, and etoposide) for diffuse large B-cell lymphoma, and dexamethasone for multiple myeloma.
  • What are researchers hoping to achieve by using lenalidomide in these trials? Researchers are investigating whether lenalidomide can improve outcomes such as overall response rates, progression-free survival, and overall survival in various cancers. They are also studying its potential as a maintenance therapy after other treatments, such as stem cell transplantation in multiple myeloma.
  • What are some potential side effects of lenalidomide being monitored in these trials? Common side effects being monitored include fatigue, diarrhea, neutropenia (low white blood cell count), thrombocytopenia (low platelet count), and anemia. Researchers are also watching for more serious adverse events such as blood clots, secondary malignancies, and tumor flare reactions, especially in patients with chronic lymphocytic leukemia.

Ongoing Clinical Trials on Lenalidomide

  • A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain Sweden

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Croatia Czechia Denmark Estonia +10

  • Comparing CT-P44 and Darzalex Faspro with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma

    Recruiting

    1 1 1 1
    Investigated drugs:
    Poland Spain

  • Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland France Germany Greece Italy The Netherlands +2

  • Study on Epcoritamab for Patients with Relapsed or Refractory Large B Cell Lymphoma

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Safety and Effects of Inobrodib, Betamethasone Sodium Phosphate, and Dimethyl Fumarate in Patients with Advanced Blood and Bone Marrow Cancers

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +5

Glossary

  • Lenalidomide: An immunomodulatory drug used to treat various types of cancer, including multiple myeloma and certain blood disorders. It works by enhancing the immune system's ability to fight cancer cells and by inhibiting the growth of new blood vessels that feed tumors.
  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell found in bone marrow. It can lead to bone pain, frequent infections, and other complications.
  • Chronic Lymphocytic Leukemia (CLL): A type of blood cancer that affects lymphocytes, a type of white blood cell. It typically progresses slowly and is characterized by an accumulation of abnormal lymphocytes in the blood and bone marrow.
  • Mantle Cell Lymphoma: A rare type of B-cell non-Hodgkin lymphoma that typically affects lymph nodes and can spread to other tissues. It is often aggressive and can be challenging to treat.
  • Myelodysplastic Syndromes (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells. It can lead to anemia, infections, or easy bleeding and can sometimes progress to acute myeloid leukemia.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse. It is an important measure of the effectiveness of cancer treatments in clinical trials.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment. It includes both complete and partial responses to therapy.
  • Maintenance Therapy: Treatment given to help keep cancer from coming back after it has responded to initial therapy. It may include ongoing drug therapy or other forms of treatment.
  • Autologous Stem Cell Transplantation (ASCT): A procedure in which a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to help restore the bone marrow's ability to produce blood cells.
  • Tumor Flare Reaction: A temporary worsening of tumor-related symptoms that can occur when treatment begins to work against the cancer. It is sometimes seen in patients with chronic lymphocytic leukemia treated with lenalidomide.

References

  1. https://clinicaltrials.gov/study/NCT01582776
  2. https://clinicaltrials.gov/study/NCT01904643
  3. https://clinicaltrials.gov/study/NCT01463670
  4. https://clinicaltrials.gov/study/NCT00424229
  5. https://clinicaltrials.gov/study/NCT02215980
  6. https://clinicaltrials.gov/study/NCT02206503
  7. https://clinicaltrials.gov/study/NCT05623020